Aspargo Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting with FDA on Sildenafil Oral Spray for the Treatment of Erectile Dysfunction
04 mai 2020 09h00 HE
|
Aspargo Laboratories, Inc.
Alignment with FDA to pursue 505(b)(2) regulatory pathway On-track for IND filing in Q3 2020 ENGLEWOOD CLIFFS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Aspargo Laboratories, Inc. (Aspargo), a...